Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.
Marshall J. Shuler, MD, FAAD
Advertisement
Articles by Marshall J. Shuler, MD, FAAD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
4
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
5